Hypoxia-inducible factor-prolyl hydroxylase domain inhibitors (HIF-PHIs) are a novel group
of drugs used to treat renal anemia, but their benefits vary among different trials. Our meta …

Background. Roxadustat is a newly listed oral hypoxia‐inducible factor‐proline enhancing
enzyme inhibitor (HIF‐PHI) in recent years. There have been some studies that have proved …

Background Anaemia is a common complication of end-stage renal disease (ESRD) that
relies on dialysis. Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) is a new …

Background Renal anemia of diabetic kidney disease (DKD) shows higher incidence rate,
earlier onset and higher severity than other chronic kidney disease (CKD). Roxadustat, an …

Anemia is a common complication of chronic kidney disease (CKD), and its prevalence rises
as the disease progresses. Intravenous or subcutaneous erythropoiesis-stimulating agents …

Anemia is a common complication of kidney disease and the prevalence increases as the
disease progresses. It worsens the quality of life of patients and increases morbidity and …

Aims This study aimed to evaluate the effects of hypoxia-inducible factor prolyl hydroxylase
inhibitors (HIF-PHIs) on iron metabolism and inflammation in dialysis-dependent chronic …

Background: Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are novel oral
agents used for renal anemia treatment. Roxadustat, a first-in-class HIF-PHI used for treating …

Background: Anemia is one of the common complications of chronic kidney disease (CKD),
and its prevalence has been arising globally. The key cause of anemia in CKD patients is …

Background Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors are an oral
treatment for anemia of chronic kidney disease (CKD). In this systematic review and meta …